Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease
Fig 3
Fluid-phase alternative pathway activation.
Observed (symbols) and simulated (lines, module 1) complement factor levels in experiments of fluid-phase AP activation in in vitro samples. (A) Inactivation of C3 in absence or presence of FB, FD, FH, and FI. (B) Formation of C3b by preassembled C3 convertases. (C) Conversion of C3b to iC3b as a function of FH concentration (790 nM (a), 393 nM (b), 197 nM (c), 98.5 nM (d), 49.3 nM (e), 12.4 nM (f), 4.50 nM (g). Dashed lines: experimental data, solid lines: model simulation). (D-F) Formation of activation markers C3a (D), Bb (E), and C3dg (F) due to spontaneous activation of AP in human serum samples. Data was obtained from [10] (A), [62] (B), [61] (C), [38,64] (D), and [63] (E,F). C3a levels from [38,64] were baseline corrected. Bb and C3dg levels from [63] were converted to molar concentrations for comparison to model results, assuming a molecular weight of 63 kDa and 38 kDa, respectively.